ConductScience.org, home

Comparison · NCT02385279-8aabdb09

MiStent® vs XIENCE EES: Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. MiStent® vs XIENCE EES: Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE). Trial comparisons, record NCT02385279-8aabdb09. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02385279-8aabdb09

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.05690.04210.0766wilson
Risk in group 20.06470.04870.0855wilson
Risk difference, group 1 minus group 2-0.00785-0.03340.0175newcombe hybrid score
Risk ratio, group 1 over group 20.8790.5821.33log
Odds ratio, group 1 over group 20.8710.5621.35log
Number needed to treat, for one fewer participant with the outcome on MiStent® than on XIENCE EES127from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1MiStent®
Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.~MiStent: Percutaneous Coronary Intervention
40703OG000
Group 2XIENCE EES
Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.~XIENCE EES: Percutaneous Coronary Intervention
45695OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE)
Description
DOCE is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a non-target vessel and clinically-indicated target lesion revascularization.
Time frame
12 months postprocedure
Population
Intention-to-treat

Source ClinicalTrials.gov

Trial

Title
Study Comparing the MiStent SES Versus the XIENCE EES Stent
NCT number
NCT02385279
Phases
NA
Conditions
Coronary Stenosis
Interventions
MiStent, XIENCE EES
Lead sponsor
ECRI bv
Results first posted
2023-05-08

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02385279-8aabdb09